Abstract
Purpose: The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma–related renal impairment (RI). Methods: Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations: All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lena-lidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m2 to 140 mg/m2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dex-amethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1544-1557 |
| Number of pages | 14 |
| Journal | Journal of Clinical Oncology |
| Volume | 34 |
| Issue number | 13 |
| DOIs | |
| State | Published - May 1 2016 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. / Dimopoulos, Meletios A.; Sonneveld, Pieter; Leung, Nelson; Merlini, Giampaolo; Ludwig, Heinz; Kastritis, Efstathios; Goldschmidt, Hartmut; Joshua, Douglas; Orlowski, Robert Z.; Powles, Raymond; Vesole, David H.; Garderet, Laurent; Einsele, Hermann; Palumbo, Antonio; Cavo, Michele; Richardson, Paul G.; Moreau, Philippe; Miguel, Jesús San; Vincent Rajkumar, S.; Durie, Brian G.M.; Terpos, Evangelos; Abildgaard, Niels; Abonour, Rafat; Alsina, Melissa; Anderson, Kenneth C.; Attal, Michel; Avet-Loiseau, Hervé; Badros, Ashraf; Bahlis, Nizar Jacques; Barlogie, Bart; Bataille, Régis; Beksaç, Meral; Belch, Andrew; Ben-Yehuda, Dina; Bensinger, Bill; Leif Bergsagel, P.; Bhutani, Manisha; Bird, Jenny; Bladé, Joan; Broijl, Annemiek; Boccadoro, Mario; Caers, Jo; Chanan-Khan, Asher; Chari, Ajai; Chen, Wen Ming; Chesi, Marta; Anthony Child, J.; Chim, Chor Sang; Chng, Wee Joo; Comenzo, Ray; Cook, Gordon; Crowley, John; Crusoe, Edvan; Dalton, William; Lee Moffitt, H.; Davies, Faith; de la Rubia, Javier; de Souza, Cármino; Delforge, Michel; Dhodapkar, Madhav; Dispenzieri, Angela; Drach, Johannes; Drake, Matthew; Du, Juan; Dytfeld, Dominik; Facon, Theirry; Fantl, Dorotea; Fermand, Jean Paul; Fernández de Larrea, Carlos; Fonseca, Rafael; Gahrton, Gösta; Garćia-Sanz, Ramón; Gasparetto, Christina; Gertz, Morie; Ghobrial, Irene; Gibson, John; Gimsing, Peter; Giralt, Sergio; Gu, Jingli; Hajek, Roman; Hardan, Izhar; Hari, Parameswaran; Hata, Hiroyuki; Hattori, Yutaka; Heffner, Tom; Hillengass, Jens; Ho, Joy; Hoering, Antje; Hoffman, James Edward; Hou, Jian; Huang, Jeffrey; Hungria, Vania; Ida, Shinsuke; Jagannath, Sundar; Jakubowiak, Andrzej J.; Johnsen, Hans Erik; Jurczyszyn, Artur; Kaiser, Martin; Kaufman, Jonathan; Kawano, Michio; Korde, Neha; Kovacs, Eva; Krishnan, Amrita; Kristinsson, Sigurdur; Kröger, Nicolaus; Kumar, Shaji; Kyle, Robert A.; Kyriacou, Chara; Lacy, Martha; Lahuerta, Juan José; Landgren, Ola; Larocca, Alessandra; Laubach, Jacob; da Costa, Fernando Leal; Lee, Jae Hoon; Leiba, Merav; Leleu, Xavier; Lentzsch, Suzanne; Lokhorst, Henk; Lonial, Sagar; Lu, Jin; Mahindra, Anuj; Maiolino, Angelo; Manasanch, Elisabet E.; Mark, Tomer; Mateos, María Victoria; Mazumder, Amitabha; McCarthy, Philip; Mehta, Jayesh; Mellqvist, Ulf Henrik; Mikhael, Joseph; Morgan, Gareth; Munshi, Nikhil; Nahi, Hareth; Nawarawong, Weerasak; Niesvizky, Ruben; Nouel, Amara; Novis, Yana; Ocio, Enrique; O'Dwyer, Michael; O'Gorman, Peter; Orfao, Alberto; Otero, Paula Rodriguez; Paiva, Bruno; Pavlovsky, Santiago; Pilarski, Linda; Pratt, Guy; Qui, Lugui; Raje, Noopur; Reece, Donna; Reiman, Anthony; Remaggi, Guillermina; Richter, Joshua; Serra, Eloísa Riva; Morales, Angelina Rodríguez; Romeril, Kenneth R.; Roodman, David; Rosiñol, Laura; Rossi, Adriana; Roussel, Murielle; Russell, Stephen; Schjesvold, Fredrik; Schots, Rik; Sevcikova, Sabina; Sezer, Orhan; Shah, Jatin J.; Shimizu, Kazuyuki; Shustik, Chaim; Siegel, David; Singhal, Seema; Spencer, Andrew; Stadtmauer, Edward; Stewart, Keith; Tan, Daryl; Terragna, Carolina; Tosi, Patrizia; Tricot, Guido; Turesson, Ingemar; Usmani, Saad; Van Camp, Ben; Van de Donk, Niels; Van Ness, Brian; Van Riet, Ivan; Broek, Isabelle Vande; Vanderkerken, Karin; Vescio, Robert; Vij, Ravi; Voorhees, Peter; Waage, Anders; Wang, Michael; Weber, Donna; Weiss, Brendan M.; Westin, Jan; Wheatley, Keith; Zamagni, Elena; Zonder, Jeffrey; Zweegman, Sonja.
In: Journal of Clinical Oncology, Vol. 34, No. 13, 01.05.2016, p. 1544-1557.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment
AU - Dimopoulos, Meletios A.
AU - Sonneveld, Pieter
AU - Leung, Nelson
AU - Merlini, Giampaolo
AU - Ludwig, Heinz
AU - Kastritis, Efstathios
AU - Goldschmidt, Hartmut
AU - Joshua, Douglas
AU - Orlowski, Robert Z.
AU - Powles, Raymond
AU - Vesole, David H.
AU - Garderet, Laurent
AU - Einsele, Hermann
AU - Palumbo, Antonio
AU - Cavo, Michele
AU - Richardson, Paul G.
AU - Moreau, Philippe
AU - Miguel, Jesús San
AU - Vincent Rajkumar, S.
AU - Durie, Brian G.M.
AU - Terpos, Evangelos
AU - Abildgaard, Niels
AU - Abonour, Rafat
AU - Alsina, Melissa
AU - Anderson, Kenneth C.
AU - Attal, Michel
AU - Avet-Loiseau, Hervé
AU - Badros, Ashraf
AU - Bahlis, Nizar Jacques
AU - Barlogie, Bart
AU - Bataille, Régis
AU - Beksaç, Meral
AU - Belch, Andrew
AU - Ben-Yehuda, Dina
AU - Bensinger, Bill
AU - Leif Bergsagel, P.
AU - Bhutani, Manisha
AU - Bird, Jenny
AU - Bladé, Joan
AU - Broijl, Annemiek
AU - Boccadoro, Mario
AU - Caers, Jo
AU - Chanan-Khan, Asher
AU - Chari, Ajai
AU - Chen, Wen Ming
AU - Chesi, Marta
AU - Anthony Child, J.
AU - Chim, Chor Sang
AU - Chng, Wee Joo
AU - Comenzo, Ray
AU - Cook, Gordon
AU - Crowley, John
AU - Crusoe, Edvan
AU - Dalton, William
AU - Lee Moffitt, H.
AU - Davies, Faith
AU - de la Rubia, Javier
AU - de Souza, Cármino
AU - Delforge, Michel
AU - Dhodapkar, Madhav
AU - Dispenzieri, Angela
AU - Drach, Johannes
AU - Drake, Matthew
AU - Du, Juan
AU - Dytfeld, Dominik
AU - Facon, Theirry
AU - Fantl, Dorotea
AU - Fermand, Jean Paul
AU - Fernández de Larrea, Carlos
AU - Fonseca, Rafael
AU - Gahrton, Gösta
AU - Garćia-Sanz, Ramón
AU - Gasparetto, Christina
AU - Gertz, Morie
AU - Ghobrial, Irene
AU - Gibson, John
AU - Gimsing, Peter
AU - Giralt, Sergio
AU - Gu, Jingli
AU - Hajek, Roman
AU - Hardan, Izhar
AU - Hari, Parameswaran
AU - Hata, Hiroyuki
AU - Hattori, Yutaka
AU - Heffner, Tom
AU - Hillengass, Jens
AU - Ho, Joy
AU - Hoering, Antje
AU - Hoffman, James Edward
AU - Hou, Jian
AU - Huang, Jeffrey
AU - Hungria, Vania
AU - Ida, Shinsuke
AU - Jagannath, Sundar
AU - Jakubowiak, Andrzej J.
AU - Johnsen, Hans Erik
AU - Jurczyszyn, Artur
AU - Kaiser, Martin
AU - Kaufman, Jonathan
AU - Kawano, Michio
AU - Korde, Neha
AU - Kovacs, Eva
AU - Krishnan, Amrita
AU - Kristinsson, Sigurdur
AU - Kröger, Nicolaus
AU - Kumar, Shaji
AU - Kyle, Robert A.
AU - Kyriacou, Chara
AU - Lacy, Martha
AU - Lahuerta, Juan José
AU - Landgren, Ola
AU - Larocca, Alessandra
AU - Laubach, Jacob
AU - da Costa, Fernando Leal
AU - Lee, Jae Hoon
AU - Leiba, Merav
AU - Leleu, Xavier
AU - Lentzsch, Suzanne
AU - Lokhorst, Henk
AU - Lonial, Sagar
AU - Lu, Jin
AU - Mahindra, Anuj
AU - Maiolino, Angelo
AU - Manasanch, Elisabet E.
AU - Mark, Tomer
AU - Mateos, María Victoria
AU - Mazumder, Amitabha
AU - McCarthy, Philip
AU - Mehta, Jayesh
AU - Mellqvist, Ulf Henrik
AU - Mikhael, Joseph
AU - Morgan, Gareth
AU - Munshi, Nikhil
AU - Nahi, Hareth
AU - Nawarawong, Weerasak
AU - Niesvizky, Ruben
AU - Nouel, Amara
AU - Novis, Yana
AU - Ocio, Enrique
AU - O'Dwyer, Michael
AU - O'Gorman, Peter
AU - Orfao, Alberto
AU - Otero, Paula Rodriguez
AU - Paiva, Bruno
AU - Pavlovsky, Santiago
AU - Pilarski, Linda
AU - Pratt, Guy
AU - Qui, Lugui
AU - Raje, Noopur
AU - Reece, Donna
AU - Reiman, Anthony
AU - Remaggi, Guillermina
AU - Richter, Joshua
AU - Serra, Eloísa Riva
AU - Morales, Angelina Rodríguez
AU - Romeril, Kenneth R.
AU - Roodman, David
AU - Rosiñol, Laura
AU - Rossi, Adriana
AU - Roussel, Murielle
AU - Russell, Stephen
AU - Schjesvold, Fredrik
AU - Schots, Rik
AU - Sevcikova, Sabina
AU - Sezer, Orhan
AU - Shah, Jatin J.
AU - Shimizu, Kazuyuki
AU - Shustik, Chaim
AU - Siegel, David
AU - Singhal, Seema
AU - Spencer, Andrew
AU - Stadtmauer, Edward
AU - Stewart, Keith
AU - Tan, Daryl
AU - Terragna, Carolina
AU - Tosi, Patrizia
AU - Tricot, Guido
AU - Turesson, Ingemar
AU - Usmani, Saad
AU - Van Camp, Ben
AU - Van de Donk, Niels
AU - Van Ness, Brian
AU - Van Riet, Ivan
AU - Broek, Isabelle Vande
AU - Vanderkerken, Karin
AU - Vescio, Robert
AU - Vij, Ravi
AU - Voorhees, Peter
AU - Waage, Anders
AU - Wang, Michael
AU - Weber, Donna
AU - Weiss, Brendan M.
AU - Westin, Jan
AU - Wheatley, Keith
AU - Zamagni, Elena
AU - Zonder, Jeffrey
AU - Zweegman, Sonja
N1 - Publisher Copyright: © 2016 by American Society of Clinical Oncology.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Purpose: The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma–related renal impairment (RI). Methods: Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations: All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lena-lidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m2 to 140 mg/m2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dex-amethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).
AB - Purpose: The aim of the International Myeloma Working Group was to develop practical recommendations for the diagnosis and management of multiple myeloma–related renal impairment (RI). Methods: Recommendations were based on published data through December 2015, and were developed using the system developed by the Grading of Recommendation, Assessment, Development, and Evaluation Working Group. Recommendations: All patients with myeloma at diagnosis and at disease assessment should have serum creatinine, estimated glomerular filtration rate, and electrolytes measurements as well as free light chain, if available, and urine electrophoresis of a sample from a 24-hour urine collection (grade A). The Chronic Kidney Disease Epidemiology Collaboration, preferably, or the Modification of Diet in Renal Disease formula should be used for the evaluation of estimated glomerular filtration rate in patients with stabilized serum creatinine (grade A). International Myeloma Working Group criteria for renal reversibility should be used (grade B). For the management of RI in patients with multiple myeloma, high fluid intake is indicated along with antimyeloma therapy (grade B). The use of high-cutoff hemodialysis membranes in combination with antimyeloma therapy can be considered (grade B). Bortezomib-based regimens remain the cornerstone of the management of myeloma-related RI (grade A). High-dose dexamethasone should be administered at least for the first month of therapy (grade B). Thalidomide is effective in patients with myeloma with RI, and no dose modifications are needed (grade B). Lenalidomide is effective and safe, mainly in patients with mild to moderate RI (grade B); for patients with severe RI or on dialysis, lena-lidomide should be given with close monitoring for hematologic toxicity (grade B) with dose reduction as needed. High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m2 to 140 mg/m2) is feasible in patients with RI (grade C). Carfilzomib can be safely administered to patients with creatinine clearance > 15 mL/min, whereas ixazomib in combination with lenalidomide and dex-amethasone can be safely administered to patients with creatinine clearance > 30 mL/min (grade A).
UR - http://www.scopus.com/inward/record.url?scp=84965050407&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84965050407&partnerID=8YFLogxK
U2 - 10.1200/JCO.2015.65.0044
DO - 10.1200/JCO.2015.65.0044
M3 - Article
C2 - 26976420
AN - SCOPUS:84965050407
VL - 34
SP - 1544
EP - 1557
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 13
ER -